drugset
drugset / Trial / NCT05853835

First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641

NCT05853835 ↗

Phase 1 Completed 72 enrolled LAPIX Therapeutics Inc.
RandomizedSequentialTriple-blindTreatment

Summary

A Phase I First-in-Human, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adult Volunteers to Evaluate Safety, Tolerability, and Pharmacokinetics after Single and Multiple Oral Dose of LPX-TI641.

Timeline

Start
2023-10-30
Primary completion
2024-08-15
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LPX-TI641 Small molecule — Oral

Indications

multiple sclerosis